Neko Health stock

Neko Health has raised a total of SEK 3.77 billion in capital, according to our records. The amount raised in each funding round is shown once you create an account.

In its latest share issue, in January 2025, Neko Health was valued at SEK 17.3 billion post-money. The price was SEK 1,486 per share.

The largest shareholders in Neko Health are Antheia Investment AB (26.75 %), Hjalmar Nilsonne (19.97 %), and PrimaMateria Invest 3 AB (15.43 %). The figures come from Eivora and were last updated in September 2026.

In 2025, Neko Health had revenue of SEK 147 million. It reported a loss of SEK 678 million for the year.

The CEO of Neko Health is Hjalmar Nilsonne. The board is chaired by Daniel Georg Ek.

Neko Health is an unlisted company, meaning the shares are not traded on any exchange. Instead, transactions take place through direct transfers between parties, known as secondary trading, typically via a specialised platform for unlisted shares such as Accumeo. For larger international companies, investing through fund structures that pool several investors into a single ownership vehicle is also common. This allows smaller minimum investments and opens up access to international companies for non-institutional investors.

Yes, it is possible to buy existing shares in Neko Health through secondary trading. On Accumeo you create a free account, submit an expression of interest with an amount and any conditions, and may then be matched with a seller. Once both parties have signed the customer agreement, a share transfer agreement is drawn up covering price, share count, and settlement date.

Yes, secondary trading is often the only realistic route to liquidity for an unlisted holding before an IPO or acquisition. Via Accumeo you submit an expression of interest with a share count and target price, and a match may be made with a potential buyer. The sale is executed through a share transfer agreement and registered either via Euroclear or directly in the company's share register, depending on how ownership is administered.

Unlisted companies have no continuous share price because there is no continuous exchange trading. The value is instead based on the latest secondary-market trade or on the price per share from the most recent share issuance. Accumeo shows both historical transaction prices and current bid/ask quotes, providing a combined reference point for pricing.

The value of an unlisted share is most often based on the latest trade — the price buyer and seller agreed in a transaction — or on the latest funding round, where the company and its investors agreed a price for the newly issued shares. These are the reference points shown on Accumeo's platform. It is, however, important to form your own view of value by examining the company's prospects. Financial reports, growth opportunities, market position, and comparable transactions in the sector all help to build a better picture of how the business may develop. Useful information can be found on the company's own website, via Accumeo's platform, and on services like allabolag.se.

No, Neko Health is an unlisted company and its shares are not traded on the Stockholm Stock Exchange, NYSE, or any other regulated marketplace. Shares are instead traded through secondary trading between investors, typically via a specialised platform such as Accumeo.

No. Neko Health keeps its own share register, usually through a digital service. You are entered there when ownership transfers, rather than the shares arriving in your brokerage account — ownership is just as binding, but it will not appear at your usual broker.

Yes. The articles of association carry transfer restrictions, giving existing shareholders the right to take over the shares ahead of an outside buyer. Expect the transfer to take around 30 days longer while that runs its course.